Another study on xenograft mouse models suggested that the combination of mTORC1 inhibition with ferroptosis induction resulted in tumor regression in PI3K-mutated breast cancer and PTEN-defective prostate cancer (Yi et al., 2020). Here, PTEN is linked to prostate carcinoma.